Vitamin D status and cognitive functioning in patients with relapsing remitting multiple sclerosis * a neuropsychological and functional MRI approach - Vitamin D status and cognition in MS

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- A definite, MRI-confirmed, RRMS (Polman et al., 2005);
•- A disease duration since the onset of first symptoms of *5 years;
•- An age of 18-50 years;
•- Treatment with either IFN-beta (Avonex, Betaferon, Rebif) or Glatiramer Acetate (Copaxone) or no disease modulating drugs (DMD) treatment;
•- No exacerbation within 6 weeks prior to assessment;
•- Vitamin D supplementation <<=20 *g/d (800 IU/d);
•- A serum 25-hydroxyvitamin D (25(OH)D) level available within 1 year prior to inclusion, being either <50 nmol/L OR >100 nmol/L.

•- Progressive disease without relapses;
•- Treatment with any immune suppressive or immune modulating drug or than IFN-beta or Glatiramer Acetate within 3 months prior to assessment;
•- Cognitive dysfunction reported by spouses, family or MS nurses, neurologist or reported by previous neuropsychological research
•- Presence of a depression as detected with the HADS (depression score *8;
•- Vitamin D supplementation more than 20 *g/d (800 IU/d);
•- Severe visual and/or verbal limitations interfering with neuropsychological testing;
•- Contraindications for MRI examination.

发起方

Medisch Universitair Ziekenhuis Maastricht